Document:

fprx-ex1037_375.htm

CONFIDENTIAL

Exhibit 10.37

 

Amendment No. 1 to the Confidential Consulting Agreement

This Amendment No. 1 to the Consulting Agreement (this “Amendment”), effective October 13, 2018 (the “Amendment Effective Date”), is made and entered into by and between Five Prime Therapeutics, Inc., a Delaware corporation (“Client”), and FLG Partners, LLC, a California limited liability company (“FLG”).  

Background

A.Client and FLG are parties to the Confidential Consulting Agreement, dated April 13, 2018 (the “Agreement”).  

B.Pursuant to Section 11(G) of the Agreement, any term or provision of the Agreement may be amended only by a writing signed by the parties.

C.Client and FLG desire to amend certain provisions of the Agreement as set forth in this Amendment. 

Now, therefore, Client and FLG agree as follows:

1.Amendment of the Agreement. Client and FLG agree to amend the terms of the Agreement as provided below, effective as of the Amendment Effective Date.  Capitalized terms used in this Amendment that are not otherwise defined herein shall have the same meanings as such terms are given in the Agreement.  

2.Term.  Section 6 of Exhibit A to the Agreement is hereby amended and restated in its entirety as set forth below:

“Term. The later of twelve months from the Effective Date or upon the completion of Services, unless earlier terminated pursuant to Paragraph 4 of the Agreement.”

3.Miscellaneous.

3.1Full Force and Effect.  All terms and conditions set forth in the Agreement that are not amended hereby shall remain in full force and effect.

3.2Entire Agreement.  The Agreement, as amended by this Amendment, sets forth the entire understanding of Client and FLG relating to the subject matter thereof and supersedes all prior agreements and understandings between Client and FLG relating to the subject matter thereof.

3.3Modification.  This Amendment may not be modified or amended in any way unless done so in accordance with Section 11(G) of the Agreement.

3.4Counterparts. This Amendment may be executed in counterparts, each of which shall constitute an original and both of which, when taken together, shall constitute one agreement.  The exchange of a fully executed Amendment (in counterparts or otherwise) by electronic transmission, including by email, or facsimile shall be sufficient to bind Client and FLG to the terms and conditions of this Amendment.

1

LGL-7045

CONFIDENTIAL

In Witness Whereof, Client and FLG have executed this Amendment with effect as of the Amendment Effective Date.

 

		
	
Five Prime Therapeutics, Inc.

 

 

By:  /s/ Jeff Coon

 

Name: Jeff Coon

 

Title: SVP, Human Resources
	
FLG Partners, LLC

 

 

By: /s/ Jeffrey Kuhn

 

Name: Jeffrey Kuhn

 

Title: Administrative Partner

 

 

 

2

LGL-7045fprx-ex1042_370.htm

Exhibit 10.42

AMENDMENT No. 1

to the

NON-EXCLUSIVE LICENSE AGREEMENT

Dated 6 February 2012

Between

LONZA SALES AG

and

FIVE PRIME THERAPEUTICS, INC.

and

BIOWA, INC.

 

 

LGL-2015

B15265/IS/KJ/31May13

[***] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

 

THIS AMENDMENT is made the 6th day of June, 2013

BETWEEN

BIOWA, INC., a Delaware corporation, with a principal place of business at 9420 Athena Circle, La Jolla, California 92037, USA ("BioWa")

AND

LONZA SALES AG incorporated and registered in Switzerland whose registered office is at Muenchensteinerstrasse 38, CH-4002, Basel, Switzerland, ("Lonza")

(together the "Licensor")

AND

FIVE PRIME THERAPEUTICS, INC. of Two Corporate Drive, South San Francisco,
California 94080, USA ("Licensee").

WHEREAS

	
A.
	
Licensor and Licensee entered into a Non-Exclusive License Agreement dated 6 February 2012 (hereinafter referred to as the "Agreement") under which Licensor released materials to Licensee for the purposes of the Commercial License (all as therein defined); and

	
B.
	
Licensee now wishes to provide certain materials to third parties in connection with Licensee's further use of the Licensed Technology; and

	
C.
	
Licensor and Licensee now wish to amend the terms of the Agreement.

NOW THEREFORE in consideration of the mutual promises and covenants contained herein and other good and valuable consideration the sufficiency of which is acknowledged it is hereby agreed by and between the parties to amend the Agreement as follows:

B15265/IS/KJ/31May13

[***] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

	
1.
	
The words and phrases defined in the Agreement shall have the same meanings in this Amendment. In addition, the following term shall have the meaning shown:

"[***]" means [***] of [***].

	
2.
	
Subject to clause 3 below, following signature of this Amendment No. 1 to the Agreement by the parties, Licensee shall be permitted to supply to [***] the following materials:

	
 
	
1.
	
The Vector [***] identified in clause 3.1 (a) of the Agreement and related Licensor Know-How; and

	
 
	
2.
	
[***] of Potelligent® CHOK1SV from which [***] to be used as a [***].

(together, "the Characterisation Materials")

	
3.
	
Licensor hereby consents to Licensee supplying the Characterisation Materials to [***] for the sole purpose of [***] using the Characterisation Materials for [***]; provided that [***] shall not use the Characterisation Materials or cause or permit the Characterisation Materials to be used in any way for human in vivo studies or for commercial purposes including but without limitation the manufacture, use, marketing and sale of any Product or any product containing or derived from a Product.

	
4.
	
Licensee shall ensure that [***] use the Characterisation Materials solely as expressly permitted in clause 3 above and for no other purpose whatsoever. Licensee is responsible for the strict adherence to the relevant terms of the Agreement, including this Amendment No. 1 to the Agreement, by [***].

	
5.
	
On termination or expiry, whichever occurs earlier, of the Agreement or Licensee's arrangements with [***], Licensee shall ensure that [***] destroys or returns to Licensee the Characterisation Materials supplied by Licensee to [***] under clause 3 above, as well as any materials resulting or derived therefrom.

	
6.
	
For the avoidance of doubt, Licensee hereby confirms that neither Licensee nor [***] shall perform any analysis, test, experiment, modification or reverse-engineering on any part of the Licensed Technology.

B15265/IS/KJ/31May13

[***] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

	
7.
	
Save as herein provided all other terms and conditions of the Agreement shall remain in full force and effect.

IN WITNESS WHEREOF the parties have caused this Amendment No. 1 to be executed by their respective representatives thereunto duly authorised as of the day and year first above written.

		
	
Signed for and on behalf of
LONZA SALES AG
	

/s/ Nadia Zleger

 

/s/ Jaret White

 

Nadia Zleger

Legal Counsel

 

 
TITLE
	
Signed for and on behalf of
LONZA SALES AG
	

Jaret White

Head Development

 

 
TITLE

President and CEO

 

/s/ 

 
TITLE
	
Signed for and on behalf of
BIOWA, INC.
	
 

/s/ Aron Knickerbocker 

 
 
	
Signed for and on behalf of
FIVE PRIME THERAPEUTICS, INC.
	

Aron Knickerbocker 

Senior VP-Business Development

 

 

TITLE

 

B15265/IS/KJ/31May13

[***] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.fprx-ex1043_368.htm

Execution Copy

Exhibit 10.43

 

 

 

 

AMENDMENT No. 2

 

to the

 

NON-EXCLUSIVE LICENSE AGREEMENT

 

Dated 6 February 2012

 

Between

 

BIOWA, INC.

 

and

 

LONZA SALES AG

 

and

 

 

FIVE PRIME THERAPEUTICS, INC.

 

 

 

 

LGL-4454

CONFIDENTIAL

 

[***] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

 

Execution Copy

THIS AMENDMENT No. 2 (this “Amendment”) is made the 17th day of April, 2018 (the “Effective Date”)

 

 

BETWEEN

 

BIOWA, INC., a Delaware corporation, with a principal place of business at 212 Carnegie Center, Suite 400, Princeton, NJ 08540, USA (“BioWa”)

 

AND

 

LONZA SALES AG incorporated and registered in Switzerland whose registered office is at Muenchensteinerstrasse 38, CH-4002, Basel, Switzerland, (“Lonza") 

 

(together the “Licensor”)

 

AND

 

FIVE PRIME THERAPEUTICS, INC., a Delaware corporation with a principal place of business at 111 Oyster Point Boulevard, South San Francisco, California 94080, USA (“Licensee”).  

 

WHEREAS

 

	
A.
	
Licensor and Licensee entered into a Non-Exclusive License Agreement dated 6 February 2012, as amended on 6 June 2013 (hereinafter referred to as the “Agreement”) under which (inter alia) Licensor released materials to Licensee for the purposes of the Commercial License (all as therein defined); and.

 

	
B.
	
Licensor and Licensee now wish to amend the terms of the Agreement.

 

NOW THEREFORE in consideration of the mutual promises and covenants contained herein and other good and valuable consideration the sufficiency of which is acknowledged, and intending to be legally bound, it is hereby agreed by and between the Parties to amend the Agreement as follows:

 

LGL-4454

CONFIDENTIAL

 

[***] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

 

Execution Copy

	
1.
	
Capitalized terms used in this Amendment No. 2 and not otherwise defined herein shall have the same meanings ascribed to such terms in the Agreement.  

 

	
2.
	
In accordance with Section 2.2.2 of the Agreement, Licensor hereby consents to Licensee’s written request dated December 9, 2016 that Licensor consent to: (i) the transfer of Transfected Cells by the Licensee to [***], a [***] (hereafter “[***]”) at its [***] facility only, notwithstanding the fact that the Parties understand that [***] is, as of the date of this Amendment No. 2, a Competing Contract Manufacturer; and (ii) the sublicense to [***] at its [***] facility only of the rights to make the Product only for the benefit of Licensee as granted to Licensee under Section 2.1 of the Agreement. Such sub-licensing referred to in this Amendment No. 2 shall be subject to the terms of the Agreement, including, without limitation, Sections 2.2.3 and 2.3. Licensee shall at all times remain responsible for the acts and omissions of [***] in connection with such sub-licensing as set forth in Section 2.3 of the Agreement. 

 

	
3.
	
Licensee shall pay to Lonza the initial payment of the Lonza Annual License Fee when and as applicable, in accordance with terms set out under Section 6.3 of the Agreement.

 

	
4.
	
Save as herein provided all other terms and conditions of the Agreement shall remain in full force and effect. 

 

[Remainder of page intentionally blank; signature page follows]

LGL-4454

CONFIDENTIAL

 

[***] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

 

Execution Copy

IN WITNESS WHEREOF the Parties have caused this Amendment No. 2 to be executed by their respective representatives thereunto duly authorised effective as of the day and year first above written.

 

 

Signed for and on behalf of 

	
BIOWA, INC.
	
../s/ Takeshi Masuda....................

 

	

	
Takeshi Masuda 

TITLE:  President and CEO

 

	
Signed for and on behalf of
	
.../s/ Albert Pereda.......................

LONZA SALES AG

	

	
...Senior Legal Counsel...............  TITLE

 

 

	
Signed for and on behalf of
	
.../s/ Cordula Altekrüger...............

LONZA SALES AG

	

	
...Senior Legal Counsel...............  TITLE

 

 

 

	
Signed for and on behalf of
	
.../s/ Kevin Baker........................

FIVE PRIME THERAPEUTICS, INC.

..SVP, Development Sciences....  TITLE

LGL-4454

CONFIDENTIAL

 

[***] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00292-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00292-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00292-of-00352.parquet"}]]